XML 31 R14.htm IDEA: XBRL DOCUMENT
v3.20.1

REVENUE | 12 Months Ended
--- | ---
Dec. 31, 2019
REVENUE |
REVENUE | NOTE 8 - REVENUE The following table summarizes the Company’s disaggregation of revenues:
|  | Year ended December 31,
(U.S. dollars in thousands) |  | 2017 |  | 2018 |  | 2019
Pfizer |  | $ | 12,181 |  | $ | 5,320 |  | 6,722
Brazil |  | $ | 7,061 |  | $ | 3,658 |  | 9,144
Revenues from selling goods |  | $ | 19,242 |  | $ | 8,978 |  | 15,866
Revenues from license and R&D services |  | $ | 1,836 |  | $ | 25,262 |  | 38,827
During the last quarter of 2019, the Company recognized revenues of approximately $4.5 million related to a $10.0 million future milestone payment. The Company assessed the likelihood of achieving the milestone using the most likely amount method and evaluated for the constraint by including in the transaction price variable consideration to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Based on the Company’s judgement, the milestone payment is expected to be received in the beginning of 2021.

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration